GlassScriptPhysician profile
Hilda Deleon
NPI 1407160088
$3,932.44
in general payments reported to CMS, 2019-2025
25 companies · $946 in 2025
The $946 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $1,190 · 2023: $356 · 2024: $943 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,113.76 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $710.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $436.44 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Viiv Healthcare Company | $370.80 | 2022-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $267.42 | 2021-2025 | |
| Gilead Sciences, INC. | $187.54 | 2023-2025 | Epclusa |
| Spr Therapeutics, INC | $140.62 | 2022 | |
| Lilly USA, LLC | $135.48 | 2021-2025 | Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $60.26 | 2023-2024 | Rexulti |
| Janssen Biotech, INC. | $57.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.43 | 2024 | |
| Novartis Pharmaceuticals Corporation | $51.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.77 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $42.85 | 2024 | Pifeltro, Delstrigo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.04 | 2021-2024 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.47 | 2021-2022 | |
| Emd Serono, INC. | $31.56 | 2022 | |
| Amgen INC. | $28.35 | 2024 | Repatha |
| Pfizer INC. | $23.22 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $22.49 | 2024 | |
| Dexcom, INC. | $19.59 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $16.36 | 2021 | |
| Exact Sciences Corporation | $16.21 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $13.91 | 2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilda Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.